- Home
- ST vs CNTA Comparison
ST vs CNTA Comparison
Compare ST & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ST | CNTA |
|---|---|---|
| Founded | 1916 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.1B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ST | CNTA |
|---|---|---|
| Price | $50.16 | $39.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $42.91 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $3,704,500,000.00 | $15,000,000.00 |
| Revenue This Year | $6.47 | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | $89.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.95 | $11.55 |
| 52 Week High | $53.89 | $40.26 |
Technical Indicators
Market Signals| Indicator | ST | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 62.46 |
| Support Level | $33.15 | $39.36 |
| Resistance Level | N/A | $39.86 |
| Average True Range (ATR) | 1.69 | 0.13 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 48.86 | 25.93 |
Price Performance
Historical ComparisonAbout ST Sensata Technologies Holding plc
Sensata Technologies is a global supplier of sensors and electrical protection for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. It also sells electrical protection products, like contactors and relays. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.